Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis

Pharmaceutical Research

Volumn 29, Issue 11, 2012, Pages 3040-3052

  Wang, Zhao ^a,c   Chen, Jianjun ^a   Wang, Jin ^a   Ahn, Sunjoo ^b   Li, Chien Ming ^b   Lu, Yan ^a   Loveless, Vivian S ^a   Dalton, James T ^b   Miller, Duane D ^a   Li, Wei ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b GTx Inc   (United States)

^c Frontage Laboratories Inc   (United States)

Author keywords

2 aryl 4 benzoyl imidazoles (ABI); antimelanoma; melanoma lung metastasis; multidrug resistance; tubulin polymerization inhibitor

Indexed keywords

ABI 270; ABI 274; ABI 288; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; COLCHICINE; DACARBAZINE; FIRTECAN; IMIDAZOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; PACLITAXEL; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CLASSIFICATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MELANOMA; METASTASIS INHIBITION; MICROTUBULE ASSEMBLY; MOLECULAR MODEL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR XENOGRAFT;

ANIMALS; ANIMALS, OUTBRED STRAINS; ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; COLCHICINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; FEMALE; HEK293 CELLS; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, HAIRLESS; MICE, INBRED C57BL; MICE, SCID; MICROTUBULES; NEOPLASM METASTASIS; P-GLYCOPROTEIN; TUBULIN; TUBULIN MODULATORS;

EID: 84867875182     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0726-4     Document Type: Article

References (40)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445:851-7.
2. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res. 2000;19:21-34.
3. Mandara M, Nortilli R, Sava T, Cetto GL. Chemotherapy for metastatic melanoma. Expert Rev Anticancer Ther. 2006;6:121-30.
4. Li W, Lu Y, Wang Z, Dalton JT, Miller DD. Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. Bioorg Med Chem Lett. 2007;17:4113-7.
5. Eggermontand AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer. 2011;47:2150-7.
6. Kahlerand KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges. 2011;9:277-86.
7. Roukos DH. PLX4032 and melanoma: resistance, expectations and uncertainty. Expert Rev Anticancer Ther. 2011;11:325-8.
8. Lu Y, Li CM, Wang Z, Ross 2nd CR, Chen J, Dalton JT, Li W, Miller DD. Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J Med Chem. 2009;52:1701-11.
9. Chen J, Wang Z, Li C-M, Lu Y, Vaddadya PK, Meibohma B, Dalton JT, Miller DD, Li W. Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J Med Chem. 2010;53:7414-27.
10. Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, Kromplewski M, Fouts ME, Medina D, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res. 2008;14:1111-5.
11. Zhang F, Michaelson JE, Moshiach S, Sachs N, Zhao W, Sun Y, Sonnenberg A, Lahti JM, Huang H, Zhang XA. Tetraspanin CD151 maintains vascular stability by balancing the forces of cell adhesion and cytoskeletal tension. Blood. 2011;118:4274-84.
12. Ahn S, Hwang DJ, Barrett CM, Yang J, Duke 3rd CB, Miller DD, Dalton JT. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer. Cancer Chemother Pharmacol. 2011;67:293-304.
13. Wang Z, Lu Y, Seibel W, Miller DD, Li W. Identifying novel molecular structures for advanced melanoma by ligand-based virtual screening. J Chem Inf Model. 2009;49:1420-7.
14. Chen J, Smith M, Kolinsky K, Adames V, Mehta N, Fritzky L, Rashed M, Wheeldon E, Linn M, Higgins B. Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models. Cancer Chemother Pharmacol. 2007;59:651-9.
15. Bhattacharyya B, Panda D, Gupta S, Banerjee M. Anti-Mitotic Activity of Colchicine and the Structural Basis for Its Interaction with Tubulin. Medi Res Rev. 2008;28:155-83.
16. Zmijewski MA, Li W, Zjawiony JK, Sweatman TW, Chen J, Miller DD, Slominski AT. Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells. Steroids. 2009;74:218-28.
17. Bazaa A, Pasquier E, Defilles C, Limam I, Kessentini-Zouari R, Kallech-Ziri O, El Battari A, Braguer D, El Ayeb M, Marrakchi N, Luis J. MVL-PLA2, a snake venom phospholipase A2, inhibits angiogenesis through an increase in microtubule dynamics and disorganization of focal adhesions. PLoS One. 2010;5:e10124.
18. Tong YG, Zhang XW, Geng MY, Yue JM, Xin XL, Tian F, Shen X, Tong LJ, Li MH, Zhang C, Li WH, Lin LP, Ding J. Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol Pharmacol. 2006;69:1226-33.
19. Guo W, Wu S, Liu J, Fang B. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res. 2008;68:7403-8.
20. Gourdeau H, Leblond L, Hamelin B, Dong K, Ouellet F, Boudreau C, Custeau D, Richard A, Gilbert MJ, Jolivet J. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development. Clin Cancer Res. 2004;10:7692-702.
21. Povlsenand CO, Jacobsen GK. Chemotherapy of a human malignant melanoma transplanted in the nude mouse. Cancer Res. 1975;35:2790-6.
22. Xu L, Begum S, Hearn JD, Hynes RO. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci U S A. 2006;103:9023-8.
23. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 2004;428:198-202.
24. Salmon SE. Human tumor clonogenic assays: growth conditions and applications. Cancer Genet Cytogenet. 1986;19:21-8.
25. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm. 1999;14:31-6.
26. Stafford SJ, Schwimer J, Anthony CT, Thomson JL, Wang YZ, Woltering EA. Colchicine and 2-methoxyestradiol Inhibit Human Angiogenesis. J Surg Res. 2005;125:104-8.
27. Li CM, Lu Y, Narayanan R, Miller DD, Dalton JT. Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazoles. Drug Metab Dispos. 2010;38:2032-9.
28. Kidera Y, Tsubaki M, Yamazoe Y, Shoji K, Nakamura H, Ogaki M, Satou T, Itoh T, Isozaki M, Kaneko J, Tanimori Y, Yanae M, Nishida S. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway. J Exp Clin Cancer Res. 2010;29:127.
29. Lavelle F, Gueritte-Voegelein F, Guenard D. Taxotere: from yew's needles to clinical practice. Bull Cancer. 1993;80:326-38.
30. Nelson RL. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. Med Pediatr Oncol. 1982;10:115-27.
31. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest EE. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol. 2006;24:1491-8.
32. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58.
33. Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M, Cianfriglia M, Ciervo A, Caraglia M, Budillon A, Meo G, Arancia G, Molinari A. The multidrug transporter P-glycoprotein: a mediator of melanoma invasion? J Invest Dermatol. 2008;128:957-71.
34. Berger W, Hauptmann E, Elbling L, Vetterlein M, Kokoschka EM, Micksche M. Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. Int J Cancer. 1997;71:108-15.
35. Diestra JE, Scheffer GL, Catala I, Maliepaard M, Schellens JH, Scheper RJ, Germa-Lluch JR, Izquierdo MA. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol. 2002;198:213-9.
36. Li CM, Wang Z, Lu Y, Ahn S, Narayanan R, Kearbey JD, Parke DN, Li W, Miller DD, Dalton JT. Biological activity of 4-substituted methoxybenzoyl-aryl- thiazole: an active microtubule inhibitor. Cancer Res. 2011;71:216-24.
37. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-36.
38. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361-98.
39. Tahir SK, Kovar P, Rosenberg SH, Ng SC. Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin. Biotechniques. 2000;29:156-60.
40. Nikolinakosand P, Heymach JV. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J Thorac Oncol. 2008;3:S131-134.